金融商品のアラートを作成するための参加
経済指標と以下の著者によるコンテンツ
無料登録 すでにアカウントがありますか？ ログイン
🟢 市場は上昇しています。当社コミュニティの12万人を超えるメンバーは、すべてそれにどう対応すべきか知っています。
お客様もお分かりですよね。
40%割引で開始
お客様もお分かりですよね。
49.43
+0.60
+1.23%
- モーニングスターの評価:
- 総資産: 2.49B
Eventide Gilead I
49.43
+0.60
+1.23%
ETILX 概要
このページではEventide Gilead Class Iの基本的な企業情報をご覧になれます。 ETILX の主要な経営陣、総資産、投資戦略、連絡先情報など。
連絡先
役員トップ
| 名前 | タイトル | 以来 | まで |
|---|---|---|---|
| Anant Goel | Portfolio Manager | 2022 | now |
| 伝記 | Anant Goel serves as Portfolio Manager for the Eventide Exponential Technologies Fund and Senior Research Analyst on other Eventide funds. Mr. Goel has a diverse background having grown up and lived in India, Hong Kong, UK, USA and China, which combined with his academic and professional interests, allow him to incorporate a diverse set of perspectives in his investment decision process. He has been passionate about responsible investing from early in his career. He has served as a Research Analyst at Eventide since 2016, leading its technology focused research. In 2015, during his M.B.A. program, he worked at Adage Capital Management, a long/short hedge fund. From 2011-2014, he served as an Analyst for NewQuest Capital Partners, a Private Equity firm in Hong Kong, where he was responsible for evaluating new investment opportunities for funds across Asia. From 2008-2011, he lived and worked in Beijing, China where he studied Mandarin and worked on start-up companies and other investment projects. Mr. Goel holds an M.B.A. from the MIT Sloan School of Management where he was selected as a Teaching Assistant (TA) for finance courses for both Executive M.B.A. and M.B.A. students. He also holds a Bachelors of Science (HONS) from the University of Warwick, UK in Economics. | ||
| Finny Kuruvilla | Resident | 2008 | now |
| 伝記 | Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s mid-cap growth and healthcare & life sciences strategies, a Managing Director for Eventide’s private fund, as well as Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech. | ||
| David Barksdale | Portfolio Manager | 2010 | 2018 |
| 伝記 | Mr. Barksdales has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and tactical asset allocation. He holds a bachelor's degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis. Prior to joining the portfolio management team in 2008, Mr. Barksdale served as a Senior Services Manager with Cadence Design Systems, an information technology company, from October 2005 until November 2008. | ||
Eventide Gilead Class Iについての考えを書いてください
本当にこのチャートを削除しますか
削除 キャンセル
添付のチャートを新しいチャートと置き換えますか？
置き換える キャンセル
コメントガイドライン
コメントにチャートを挿入する
ブロックを確認
本当に%USER_NAME%をブロックしたいですか。
ブロックすると、あなたと%USER_NAME%はお互いのInvesting.comへの投稿を見ることができなくなります。
%USER_NAME%は無事ブロックリストに追加されました
この人のブロックを解除したばかりなので、再度ブロックするには48時間待つ必要があります。
このコメントを報告してください
このコメントについて下記のように感じます
コメントに印がつきました
ありがとうございます!
報告は、確認のため管理担当に送られました